by Lupus Foundation, Ohio | Jul 16, 2026 | Lupus Foundation of America, News & Events
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to EMD Serono’s investigational drug, enpatoran, for the treatment of systemic lupus erythematosus (SLE) in those with active cutaneous skin manifestations. This post was...
by Lupus Foundation, Ohio | Jul 14, 2026 | Lupus Foundation of America, News & Events
Holly Wobma, MD, Ph.D., Instructor of Pediatrics, Harvard Medical School. Dr. Wobma will be studying CAR-Treg’s capacity to restore immune balance and subsequent disease remission in children with lupus. This post was originally published on this...
by Lupus Foundation, Ohio | Jul 14, 2026 | Lupus Foundation of America, News & Events
A new study found a lectin-based test can effectively detect certain complex sugar molecules (glycans) on the Fc region of immunoglobulin (IgG) antibodies. The lectin-based test may eventually help to spot early changes in glycosylation which has been linked to...
by Lupus Foundation, Ohio | Jul 13, 2026 | Lupus Foundation of America, News & Events
An international group of lupus researchers have developed a new measurement tool to assess brain fog and cognitive symptoms in people with systemic lupus erythematosus (SLE). This post was originally published on this...
by Lupus Foundation, Ohio | Jul 10, 2026 | Lupus Foundation of America, News & Events
New research is shedding light on the biological mechanisms that may help explain why systemic lupus erthyematosus (SLE) and other autoimmune diseases are more common in women. This study received early funding from the Lupus Foundation of America’s Gina M. Finzi...
by Lupus Foundation, Ohio | Jul 2, 2026 | Lupus Foundation of America, News & Events
A new study found that people with systemic lupus erythematosus (SLE) may face a significantly higher risk of developing chronic kidney disease (CKD), cardiovascular complications and premature death, even if they do not have lupus nephritis (LN) and have normal...
